Rhythm Pharmaceuticals’ obesity drug cuts BMI by up to 18.8% in two-year trial

Summary
Long-term trial findings presented at ObesityWeek 2026 showed sustained reductions in body mass index among patients receiving the therapy.
Description from The Hindu.
Who is covering this
-
Rhythm Pharmaceuticals’ obesity drug cuts BMI by up to 18.8% in two-year trial
Long-term trial findings presented at ObesityWeek 2026 showed sustained reductions in body mass index among patients receiving the therapy.
Comments
Comments need JavaScript.